URGN
Urogen Pharma Ltd
Price:  
9.67 
USD
Volume:  
741,549.00
Israel | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

URGN WACC - Weighted Average Cost of Capital

The WACC of Urogen Pharma Ltd (URGN) is 7.8%.

The Cost of Equity of Urogen Pharma Ltd (URGN) is 8.55%.
The Cost of Debt of Urogen Pharma Ltd (URGN) is 5.00%.

Range Selected
Cost of equity 7.30% - 9.80% 8.55%
Tax rate 2.00% - 2.40% 2.20%
Cost of debt 5.00% - 5.00% 5.00%
WACC 6.8% - 8.7% 7.8%
WACC

URGN WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.75 0.88
Additional risk adjustments 0.0% 0.5%
Cost of equity 7.30% 9.80%
Tax rate 2.00% 2.40%
Debt/Equity ratio 0.28 0.28
Cost of debt 5.00% 5.00%
After-tax WACC 6.8% 8.7%
Selected WACC 7.8%